I receive funding from the US National Institutes of Health for research into the roles of FXI and other plasma proteins in thrombosis and inflammation. I receive or have received consulting fees from companies with interests in targeting FXI or FXIa for therapeutic purposes (Anthos Therapeutics, Aronora, Bayer, Bristol-Myers Squibb, Ionis, Janssen, and Novartis), including Bayer, the sponsor of the PACIFIC-AF trial, but unrelated to asundexian. I serve, or have served, on boards of clinical trials of FXIa inhibitors run by Bristol-Myers Squibb and Janssen and have received travel honoraria to attend meetings at the invitation of Anthos Therapeutics.